Broken String Biosciences

The INDUCE-seq™ platform is a game changing #technology for the development of advanced #therapies that are safer by design, but what is it? Watch this video to learn how the platform precisely characterizes and maps DNA double-strand breaks using Next Generation Sequencing. Leveraging a novel PCR-free approach, the platform provides data-driven, actionable insights across the discovery, pre-clinical and clinical development stages to unlock new therapeutic targets within the genome and to advance gene editing programs. 🧪 #CellTherapy #GeneTherapy 

Spreading Christmas Cheer for a Great Cause! On Christmas Jumper Day, our team came together to celebrate and support Save the Children UK in their mission to create brighter futures for children around the world. With everyone dressed in their festive knits, we also had a special contribution from our very own Claire Bevis-Mott, Director of Product Development who showcased her incredible talent by creating beautiful Amigurumi crochet pieces! These handmade treasures added a unique touch to our fundraiser, helping us raise an amazing £207 for this worthy cause. A huge thank you to Claire and to everyone who participated and donated—you’ve made a real difference. #ChristmasJumperDay #SaveTheChildren #TeamSpirit #CharityFundraising #MakingADifference

We're pleased to announce that our Chief Scientific Officer, Professor Simon Reed, will be speaking tomorrow morning at the 5th Genome Editing Therapeutics Summit (formerly the CRISPR 2.0 summit). He will be showcasing the use of our platform technology, INDUCE-seq®, in gene-editing programs to develop safe, precise, and effective therapies. Can't attend the conference but want to learn more? Download our introductory webinar here: https://lnkd.in/ec8FwF9z #GenomeEditing #CRISPR #CGT

We’re heading to the Genome Editing Therapeutics Summit! This is a unique opportunity to connect with our leadership team and discover how we’re advancing the field of cell and gene therapies. From groundbreaking innovations like INDUCE-seq® to new approaches in product development, we’re looking forward to engaging in conversations that drive progress in genome editing. We’d love to connect—reach out to schedule a meeting with our team! #GenomeEditing #GeneTherapy #Innovation

Watch Our Chief Commercial Officer Steve Becker share our mission in Gene-Editing Safety. In this short video recorded by IBTV, Steve discusses how we are leading the charge in genomic integrity for safer, more effective gene-editing therapies. This conversation spotlights the incredible work our team is doing to support the next generation of gene-editing advancements that could reshape patient health outcomes worldwide.   Watch the full video here: https://lnkd.in/e-GXi943   Thank you to IBTV  for capturing our story and helping us showcase our dedication to advancing the science of gene editing.

We’re thrilled to announce that we have been featured in the Genomics Spotlight 2024, a showcase created by the Department for Business and Trade to highlight the UK’s cutting-edge contributions to genomics. This recognition underscores the strength and potential of the UK as a global hub for genomics business, research and innovation. The Genomics Spotlight showcases the UK’s unique capabilities, from the NHS Genomic Medicine Service—pioneering Whole Genome Sequencing in routine care—to the powerful contributions of emerging UK-based companies like ours. It’s an honor to be part of a thriving ecosystem that supports life sciences and accelerates discoveries that can transform patient care globally. This inclusion is a testament to the hard work of our team and our commitment to advancing genomic insights and technologies. Looking forward to what’s next for UK genomics on the world stage. Download the report here: https://lnkd.in/eqnn6TYC #Genomics #UKInnovation #LifeSciences #GenomicsSpotlight #HealthcareInnovation #BrokenStringBiosciences #UKLifeSciences

We’re proud to announce that our Chief Scientific Officer, Professor Simon Reed, and our Director of Alliance Management, Elisa Arthofer, have been invited to attend The Royal Society's "Transforming Our Future" conference taking place from the 7th to the 8th of November. This meeting focuses on the innovations revolutionizing gene-editing medicines and their potential to transform patient health. We’re excited to engage in conversations that could shape the future of healthcare and make gene-editing therapies more accessible for patients across the globe. #GeneEditing #CRISPR #PatientCare #FutureOfHealthcare #RoyalSociety #TransformingOurFuture

Our Director of Alliance Management Elisa Arthofer is attending the ESGCT Annual Congress this week. This conference is a vital gathering for the global gene and cell therapy community, bringing together leading experts, researchers, and industry professionals. Elisa will be exploring groundbreaking innovations and discussing how our DNA mapping technology, INDUCE-seq, can drive the development of safer and more effective gene-edited therapies. Connect with her on LinkedIn to set up a time to meet if you're also attending the ESGCT! We would love to meet you. #ESGCT2024 #GeneTherapy #CellTherapy #Innovation #Biotech #AllianceManagement

We're growing fast and looking for passionate, talented individuals to help us drive the future of precision medicine. If you're ready to make an impact in a dynamic and forward-thinking environment, we want to hear from you.   Current Open Roles: 1. Associate Director of Business Development, San Francisco, California 2. Senior Manufacturing Manager, Cambridge, East Anglia 3. Field Application Scientist, Boston, Massachusetts These roles offer a unique opportunity to work alongside leading experts in genomics, make meaningful contributions to groundbreaking projects, and grow your career in an innovative, fast-paced environment. Explore more and apply here: https://lnkd.in/eVpSqqEV Know someone who would be a perfect fit? Feel free to share or tag them in the comments! #Hiring #Genomics #Careers #Biotech

What an inspiring experience at the Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa! This year, we heard incredible stories, including Jimi Olaghere's—once a sickle cell patient, now a mountain climber. Jimi’s journey from battling this debilitating disease to conquering Mount Kilimanjaro showcases the transformative power of CRISPR-engineered therapies. His participation in a CRISPR gene-editing trial several years ago corrected the mutation behind his sickle cell disease, and with this groundbreaking therapy now approved in both the U.S. and Europe, countless others have new hope for a brighter future. Alongside these moving patient stories, our Chief Commercial Officer, Steve Becker and Elisa Arthofer, Director of Alliance Management, had the chance to connect with therapeutic developers and showcase our DNA mapping technology, INDUCE-seq. This cutting-edge platform enables the development of safer gene-edited therapies by reducing risk and saving time—accelerating the next wave of scientific breakthroughs in the field. We’re excited for the future of gene and cell therapies, and it's an honor to contribute to this innovative community!   #CellandGeneMesa #RegenerativeMedicine #GeneEditing #CRISPR #Mesa2024